UnitedHealth Group stock falls amid CMS regulatory changes and DOJ probe, presenting high volatility for investors. Insight into earnings impact and market outlook.

UnitedHealth Group's stock has dropped over 50% in 2024 amid operational disruptions and DOJ probes, despite strong ROCE. Insights on regulatory risks, Medicare cost pressures, and valuation outlook for investors.

An inadvertent leak of UnitedHealth Group's confidential document sheds light on strategic priorities and communication practices of a leading U.S. health insurer, highlighting market and regulatory dynamics.

UnitedHealth Group will announce its Q2 2025 earnings on July 29, featuring insights into its Optum and UnitedHealthcare business segments during a webcast conference.

UnitedHealth Group faces federal investigations over Medicare Advantage practices amid rising scrutiny of private Medicare plans. Explore the implications for insurance regulation and healthcare market dynamics.

UnitedHealth Group is reportedly under a DOJ criminal investigation for Medicare fraud, adding to existing probes amid leadership and financial outlook shifts.

UnitedHealth Group raises 2025 medical cost projections and appoints Stephen Hemsley as CEO amid rising patient utilization and financial outlook withdrawal.

UnitedHealth Group reports significant OptumHealth underperformance driven by higher Medicare Advantage utilization and risk adjustment challenges, raising profitability concerns and prompting strategic prioritization of patient engagement.

UnitedHealth Group lowers its 2025 revenue forecast due to increased Medicare Advantage plan usage, signaling shifts in health insurance market trends and consumer preferences.

UnitedHealth Group reports a return to profitability in Q1 2025 with $6.4B net earnings, revises 2025 earnings outlook amid Medicare Advantage and Optum challenges.